Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1374-1381

  Ley, Brett ^a   Bradford, Williamson Z ^b   Weycker, Derek ^c   Vittinghoff, Eric ^a   Du Bois, Roland M ^d   Collard, Harold R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b InterMune Inc   (United States)

^c POLICY ANALYSIS INC PAI   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; EXERCISE TEST; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GAP MODEL; GENDER; HUMAN; LUNG DIFFUSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MODEL; MORTALITY; OXYGEN SATURATION; OXYGEN THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE ASSESSMENT; SHORTNESS OF BREATH QUESTIONNAIRE; SIX MINUTE WALKING DISTANCE; ALGORITHM; FOLLOW UP; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN MEIER METHOD; MIDDLE AGED; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICS;

GAMMA INTERFERON; GAMMA1B INTERFERON; PIRFENIDONE; PYRIDONE DERIVATIVE; RECOMBINANT PROTEIN;

AGE FACTORS; AGED; ALGORITHMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERFERON-GAMMA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIDONES; RECOMBINANT PROTEINS; RISK ASSESSMENT; SEX FACTORS; STATISTICS AS TOPIC;

EID: 84928995228     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00146314     Document Type: Article

References (20)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140: 221-229.
3. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
4. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
5. du Bois RM, Albera C, Bradford WZ, et al. 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 1421-1429.
6. King TE, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
7. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377: 1760-1769.
8. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
9. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
10. Parzen M, Lipsitz SR. A global goodness-of-fit statistic for Cox regression models. Biometrics 1999; 55: 580-584.
11. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
12. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-836.
13. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
14. Kupferberg DH, Kaplan RM, Slymen DJ, et al. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil 2005; 25: 370-377.
15. Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 1150-1157.
16. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
17. Cook NR, Paynter NP. Performance of reclassification statistics in comparing risk prediction models. Biom J 2011; 53: 237-258.
18. Cook NR. Comments on 'evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI:10.1002/sim.2929). Stat Med 2008; 27: 191-195.
19. Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med 2009; 151: 767-774.
20. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: A framework for traditional and novel measures. Epidemiology 2010; 21: 128-138.